****Pipeline & lifecycle — TALAPRO-3/TALZENNA, FOURLIGHT-1/atirmociclib, tucatinib, Braftovi, Lyme, MEVPRO-1/Oric, PF-08634404, tilrekimig, HYMPAVZI, Seagen/Metsera/ADPT** [developing]** [developing]
Key Questions
What are the key results from the TALAPRO-3 Phase 3 trial?
The TALAPRO-3 Phase 3 trial showed TALZENNA combined with XTANDI achieving a radiographic progression-free survival (rPFS) hazard ratio (HR) of less than 0.63 in metastatic hormone-sensitive prostate cancer (mHSPC). A filing for approval is imminent based on these positive results.
What is the status of the FOURLIGHT-1 trial for atirmociclib?
FOURLIGHT-1 Phase 2 trial reported an HR of 0.60, supporting acceleration into Phase 3. This advances the development of atirmociclib in its targeted indication.
What rPFS benefit did tucatinib demonstrate?
Tucatinib showed a 35.9% reduction in rPFS risk in its clinical evaluation. This positions it as a promising option in its oncology setting.
How does Oric's rinzimetostat support the MEVPRO-1 trial?
Rinzimetostat data reinforces the MEVPRO-1 Phase 3 trial, planned for H2 2026 initiation with a potential $2B market opportunity. This strengthens Oric's pipeline in oncology.
What are the results of Pfizer's PF-08634404 in lung cancer trials?
PF-08634404, a PD-1/VEGF bispecific, achieved Phase 2 overall response rates (ORR) of 58-75% in NSCLC and SCLC. Phase 2/3 trials for OS in the US and a Phase 3 under Ian Waxman's NSCLC leadership are imminent.
Who is Ian Waxman and what is his new role at Pfizer?
Ian Waxman has joined Pfizer as Development Head for Thoracic Cancers and Essential Brands, focusing on NSCLC and thoracic oncology. His expertise supports upcoming trials like PF-08634404 Phase 3.
What is the efficacy and timeline for the Lyme disease vaccine?
The VALOR Phase 3 trial for the Lyme vaccine showed over 70% efficacy, with a filing expected in H2 2026 and a potential $1B market. This addresses rising cases, as noted in regions like Minnesota.
What are the recent deals involving Seagen, ADPT, and Novavax?
Pfizer's Seagen acquired ADCs and ADPT in a $890M deal; Novavax secured $30M+$500M deals with Sanofi and Pfizer for vaccines. These partnerships enhance pipeline and vaccine strategies amid oncology pruning.
TALAPRO-3 Ph3 TALZENNA+XTANDI rPFS HR<<0.63 mHSPC filing imminent; FOURLIGHT-1 Ph2 HR=0.60 Ph3 accel; tucatinib 35.9% rPFS cut; Oric rinzimetostat reinforces MEVPRO-1 Ph3 H2'26 $2B pot; PF-08634404 PD-1/VEGF bispecific Ph2 ORR 58-75% NSCLC/SCLC, Ph2/3 OS/US Ph3 imminent (Waxman NSCLC); binimetinib RASTRIC fail niche RAS-mCRC; Ian Waxman joins Thoracic/NSCLC; PF-07328948 Ph1 PK; Lyme VALOR Ph3 >70% eff H2'26 filing $1B pot; Seagen ADCs/ADPT $890M; Metsera VESPER-3 Ph2b/GLP-1; HYMPAVZI sBLA prio; PG4 pneumo; Novavax $30M+$500M; oncology pruning vs LOE $17B; Citeline 257 assets; Sidekick 83% improved.